{
    "nctId": "NCT02154776",
    "briefTitle": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.",
    "officialTitle": "A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced or Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Incidence of dose-limiting toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women with advanced (recurrent or metastatic) breast cancer who received no prior therapy for advanced disease.\n2. Patient is postmenopausal.\n3. Patient may have received \u2264 2 lines of chemotherapy for metastatic or recurrent breast cancer in the dose-escalation phase.\n4. Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory.\n5. Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.\n6. Patient must have either:\n\n   * Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria or at least one predominantly lytic bone lesion\n\nExclusion Criteria:\n\n1. Patient who received any CDK4/6 or PI3K inhibitor.\n2. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:\n\n   * History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry\n   * History of documented congestive heart failure (New York Heart Association functional classification III-IV)\n   * Documented cardiomyopathy\n   * Patient has a Left Ventricular Ejection Fraction (LVEF) \\< 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)\n   * History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.\n   * On screening, any of the following cardiac parameters: bradycardia (heart rate \\< 50 at rest), tachycardia (heart rate \\> 90 at rest), PR interval \\> 220 msec, QRS interval \\>109 msec, or QTcF \\>450 msec.\n\n   Systolic blood pressure \\>160 or \\<90 mmHg\n3. Patient is currently receiving any of the following medications:\n\n   * That are known strong inducers or inhibitors of CYP3A4.\n   * That have a known risk to prolong the QT interval or induce Torsades de Pointes.\n   * That have a narrow therapeutic window and are predominantly metabolized through CYP3A4.\n4. Certain scores on an anxiety and depression mood questionnaires",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}